CoraLite®594-conjugated ARHGDIB Monoclonal antibody

• 

  IF Staining of human tonsillitis using CL594-66054

  Immunofluorescent analysis of (4% PFA) fixed paraffin-embedded human tonsillitis tissue using CoraLite®594 ARHGDIB antibody (CL594-66054, Clone: 3E7B7 ) at dilution of 1:200. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

ARHGDIB Monoclonal Antibody for IF-P

Cat No. CL594-66054

Clone No.3E7B7

Host / Isotype

Mouse / IgG2b

Reactivity

human

Applications

IF-P

Synonyms

---

Tested Applications

• Positive IF-P detected in: human tonsillitis tissue

Recommended dilution

• Immunofluorescence (IF)-P: IF-P : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

CL594-66054 targets ARHGDIB in IF-P applications and shows reactivity with human samples.

• Tested Reactivity: human
• Host / Isotype: Mouse / IgG2b
• Class: Monoclonal
• Type: Antibody
• Immunogen: ARHGDIB fusion protein Ag9091
• Full Name: Rho GDP dissociation inhibitor (GDI) beta
• Calculated Molecular Weight: 201 aa, 23 kDa
• Observed Molecular Weight: 27 kDa
• GenBank Accession Number: BC009200
• Gene Symbol: ARHGDIB
• Gene ID (NCBI): 397
• RRID: AB_3673497
• Conjugate: CoraLite®594 Fluorescent Dye
• Excitation/Emission Maxima Wavelengths: 588 nm / 604 nm
• Form: Liquid
• Purification Method: Protein A purification
• UNIPROT ID: P52566
• Storage Buffer: PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
• Storage Conditions: Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage.

Background Information

ARHGDIB, also known as RhoGDI2, is a conserved member of the RhoGDI family and plays an important role in cell migrations. It regulates the GDP/GTP exchange reaction of the Rho proteins by inhibiting the dissociation of GDP from them, and the subsequent binding of GTP to them. It is mainly in hematopoietic, endothelial, and epithelial cells. It has been linked to tumorigenesis and metastasis. RhoGDI2 expression is downregulated in several cancer types, such as bladder, lung and lymphoma, but is upregulated in prostate and gastric cancer.